Funding Announcements

"We are delighted that DDF and LifeArc share our mission, addressing the clear need for more effective tools to provide the critical clinical trial data and analysis needed to improve the successful delivery of new CNS therapies to patients. This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers. We believe our integrated next generation platform can improve the execution of clinical trials by yielding significant time and cost savings, adding meaningful value to the next generation of CNS therapies."

"The technology developed by Oxford Nanopore is being used in a broad range of scientific research applications, including to further biomedical science, to characterise pathogens in microbiology and public health. This is an example of how institutional investors can play an important role in accelerating growth in companies that provide a wider benefit to society."

"The support from Suss ventures was key to put us in front of an early-stage fund that could act as lead investor. Their team has been extremely professional all the way through the process, looking for ways to improve our communication with prospective investors and creating a network of start-ups in similar stages. They have been and continue to be a very valuable asset for us in our current funding round and hopefully for the next ones to come."

"We believe Exscientia’s innovative use of AI to discover and design better quality drugs with greater efficiency has the potential to create important medicines faster than ever before. With the convergence of technology and biology, drug discovery is rapidly evolving in ways that will reshape the industry. The Exscientia team have been leaders in AI-based drug discovery since the field’s inception and we believe they will continue shaping its future."